Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness

Edit Stockhouse 17 Jun 2016
"With the enrollment of our first patient in the ASSENT trial, our pivotal program for AM-111 is now fully initiated," commented Thomas Meyer, Auris Medical's founder, Chairman and Chief Executive Officer ... JNK is activated following various types of cochlear insults (stress) that cause acute inner ear hearing loss and plays a key role in the apoptosis of cochlear hair cells and neurons as well as in inflammatory responses ... Contact ... ....

Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness (Auris Medical Holding AG)

Edit Public Technologies 17 Jun 2016
(Source. Auris Medical Holding AG) ... The start of ASSENT is yet another important milestone on our way toward the development of AM-111 as the first specific therapeutic for acute inner ear hearing loss.' ... About AM-111 ... JNK is activated following various types of cochlear insults (stress) that cause acute inner ear hearing loss and plays a key role in the apoptosis of cochlear hair cells and neurons as well as in inflammatory responses....

Extension of Closing Date of Entitlement Offer (Prescient Therapeutics Ltd)

Edit Public Technologies 16 Jun 2016
(Source. Prescient Therapeutics Ltd) 9e09ebd8-213a-4cf7-943d-99ff1ca3cec3.pdf ASX Release. Extension of Closing Date of Entitlement Offer. Melbourne, Australia - (16 June, 2016) - Clinical-stage oncology company Prescient Therapeutics Limited (ASX ... Item. Date* ... 22 June 2016 ... 23 June 2016 ... ENDS ... It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells....

WesternU team, international collaborators publish new findings on calpain-1 (Western University of Health Sciences)

Edit Public Technologies 16 Jun 2016
(Source. Western University of Health Sciences) ... Click here to view the article online. http.//www.cell.com/cell-reports/fulltext/S2211-1247(16)30627-1 ... The French investigators in Paris include Drs ... The Baudry team identified the critical target of calpain-1, which is responsible for normally activating a pro-survival pathway, a phosphatase previously shown to be involved in programmed cell death, or apoptosis, called PHLPP1 ... (noodl....

Karyopharm Outlines Key Selinexor Clinical Development Achievements (Karyopharm Therapeutics Inc)

Edit Public Technologies 16 Jun 2016
(Source. Karyopharm Therapeutics Inc). - Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma -. - Patient Dosing Underway in Phase 1b Clinical Trial of Selinexor in Combination with Chemotherapeutic, Targeted and Immunotherapeutic Agents - ... This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells....

How Melatonin May Benefit Depression, Autoimmune Disorders, and Cancer

Edit Mercola 16 Jun 2016
The hormone melatonin plays many important roles in your health, from helping you sleep better to strengthening your immune system, slowing down brain aging, reducing migraine attacks, protecting bone mass, and preventing cancer ... Melatonin for Sleep and Beyond ...   ... Cells throughout your body — even cancer cells — have melatonin receptors, and melatonin is in and of itself cytotoxic, meaning can induce tumor cell death (apoptosis) ... ....

Cellect Awarded NIS 3.5 Million BIRD Foundation Grant for the Development and Commercialization of Innovative ...

Edit Stockhouse 15 Jun 2016
Cellect develops an innovative technology, which enables the functional selection of stem cells based on their sensitivity to apoptosis ... The Company’s first product line will include unique containers for cell selection in an apoptosis-inducing microenvironment....

60 new medical technology jobs for Galway

Edit RTE 15 Jun 2016
The company makes a device that helps with the reduction of unwanted fat by cooling the temperature of fat cells, leading to their elimination through a process called apoptosis ... ....

ZELTIQ® Aesthetics, Inc. to establish European manufacturing facility in Galway, creating 60 jobs (Department of Jobs, Enterprise and Innovation of Ireland)

Edit Public Technologies 15 Jun 2016
(Source. Department of Jobs, Enterprise and Innovation of Ireland) News & Events. 15th June 2016. Developer of Breakthrough Noninvasive Fat Reduction CoolSculpting® Procedure. ZELTIQ® Aesthetics, Inc. (NASDAQ ... It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis....

Yale Joins PTX’s Phase 1b/2 AML Clinical Trial (Prescient Therapeutics Ltd)

Edit Public Technologies 15 Jun 2016
(Source. Prescient Therapeutics Ltd) 5535e098-6096-474f-b2ed-3925471117d7.pdf ASX Release. Yale Joins PTX's Phase 1b/2 AML Clinical Trial. Melbourne, Australia - (15 June, 2016) - Clinical-stage oncology company Prescient Therapeutics Limited (ASX ... Dr ... Dr ... Dr ... Dr ... JAZZ). ENDS ... safer ... It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells ... +61 417 601 440....

Conatus to Present at JMP Securities Life Sciences Conference

Edit Stockhouse 14 Jun 2016
SAN DIEGO, June 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ.CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York ... About Conatus Pharmaceuticals ... Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis ... Forward-Looking Statements ... MEDIA ... ....

Conatus to Present at JMP Securities Life Sciences Conference (Conatus Pharmaceuticals Inc)

Edit Public Technologies 14 Jun 2016
(Source. Conatus Pharmaceuticals Inc). SAN DIEGO, June 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ.CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York ... About Conatus Pharmaceuticals ... Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis....

PharmaMar announces the start of a pivotal study with plitidepsin in angioimmunoblastic T-cell lymphoma (Pharma Mar SA)

Edit Public Technologies 14 Jun 2016
(Source. Pharma Mar SA) ZELTIA INFORMA. PharmaMar announces the start of a pivotal study with plitidepsin in angioimmunoblastic T-cell lymphoma ... About plitidepsin. Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. It specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programed death)....
×